Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, MD PhD, Zuzan Cayci, MD, Dixie Lewis, RN,BA, Joseph E. Maakaron, MD, Murali Janakiram, MD, Andersen Bartz, Steven Payne, BS, Carol Wong, MPH, Sarah Cooley, MD, Bahram Valamehr, PhD, Yu-Waye Chu, MD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-141606

Published: 2020

Journal Articles

Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)

Sarah A. Holstein, MD PhD, Sarah Cooley, MD, Parameswaran Hari, MBBS, MD, Sundar Jagannath, MD, Catherine R Balint, BSc, William Van Der Touw, Michele L. Donato, MD, Philip L. McCarthy, MD, Paul K. Wallace, MS, PhD, Xiaokui Zhang, PhD, Robert Hariri, MD PhD, Mohamad A. Hussein, MDMBBS, Ravi Vij, MBBS

Blood (2019) 134 (Supplement_1): 4451.

https://doi.org/10.1182/blood-2019-128467

Published: 2019

Journal Articles

Bortezomib-Based Consolidation/Maintenance Therapy for Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

Shijia Zhang, MD PhD, Yucai Wang, MD, Yvonne Datta, MD, Veronika Bachanova, MD PhD, Sarah Cooley, MD

Blood (2018) 132 (Supplement 1): 3293.

https://doi.org/10.1182/blood-2018-99-113533

Published: 2018

Journal Articles

iPSC-Derived NK Cells and Anti-PD-1 Antibody Synergize to Enhance T Cell Cytokine and Cytolytic Responses Against Multiple Tumors

Frank Cichocki, PhD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Moyar Q. Ge, PhD, Dan S Kaufman, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 730.

https://doi.org/10.1182/blood-2018-99-114893

Published: 2018

Journal Articles

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Blood (2018) 132 (Supplement 1): 71.

https://doi.org/10.1182/blood-2018-99-113564

Published: 2018

Journal Articles

Outcomes of Pediatric Patients with Acute Leukemia Following Adult Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching

Michael R Verneris, MD, Tao Wang, PhD, Stephen R. Spellman, Jennifer A. Sees, MPH, Michael D. Haagenson, MS, Sarah Cooley, MD, Katharine C. Hsu, MD PhD, Katharina Fleischhauer, Katharina Fleischhauer, Dean Anthony Lee, MD PhD, Sophie Paczesny, MD PhD, Hemalatha G. Rangarajan, MD, Jeffrey S. Miller, MD, Stephanie J. Lee, MD MPH

Blood (2018) 132 (Supplement 1): 4647.

https://doi.org/10.1182/blood-2018-99-116428

Published: 2018

Journal Articles

Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+ Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS

Blood (2018) 132 (Supplement 1): 195.

https://doi.org/10.1182/blood-2018-195

Published: 2018

Journal Articles

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

Emily Chiu, PhD, Frank Cichocki, PhD, Martin Felices, PhD, Sarah Cooley, MD, Helen Chu, PhD, Moyar Q. Ge, PhD, Ryan Bjordahl, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 729.

https://doi.org/10.1182/blood-2018-99-112202

Published: 2018

Journal Articles

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Karrune Woan, MD PhD, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Svetlana Gaidarova, MS, Cameron Pride, BS, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2018-99-116459

Published: 2018

Journal Articles

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Blood (2017) 130 (Supplement 1): 656.

https://doi.org/10.1182/blood.V130.Suppl_1.656.656

Published: 2017

Journal Articles

First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation

Rizwan Romee, MD, Sarah Cooley, MD, Melissa Berrien-Elliott, PhD, Peter Westervelt, MDPhD, Michael R Verneris, MD, John E. Wagner, MD, Daniel J. Weisdorf, MD, Bruce Blazar, MD, John F DiPersio, MD PhD, Amanda F. Cashen, MD, Emily K Jeng, Amy Rock, Hing C Wong, PhD, Todd A. Fehniger, MDPhD, Jeffrey S. Miller, MD

Blood (2017) 130 (Supplement 1): 274.

https://doi.org/10.1182/blood.V130.Suppl_1.274.274

Published: 2017

Journal Articles

Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia

Sarah Cooley, MD, Fiona He, MD BS, BA, Veronika Bachanova, MD PhD, Greg M Vercellotti, MD FACP, Todd E. DeFor, MS, Julie Curtsinger, Paul Alexander Robertson, MD, Kevin C Conlon, MD, Thomas A Waldmann, MD, David H. McKenna, MD, Bruce Blazar, MD, Daniel J. Weisdorf, MD, Jeffrey S. Miller, MD

Blood (2017) 130 (Supplement 1): 2649.

https://doi.org/10.1182/blood.V130.Suppl_1.2649.2649

Published: 2017

Journal Articles

Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML

Andreas T Björklund, MD PhD MSc, Mattias Carlsten, MD PhD, Ebba Sohlberg, PhD, Trevor Clancy, Lisa Liu, Mohsen Karimi, PhD, Sarah Cooley, MD, Jeffrey S. Miller, MD, Emma Watz, Björn Engelbrekt Wahlin, Marzia Palma, MD PhD, Lotta Hansson, Per Ljungman, Eva Hellstrom-Lindberg, MD PhD, Hans-Gustaf Ljunggren, Karl-Johan Malmberg, MD PhD

Blood (2017) 130 (Supplement 1): 4458.

https://doi.org/10.1182/blood.V130.Suppl_1.4458.4458

Published: 2017

Journal Articles

NK Cell Homing and Persistence in Bone Marrow after Adoptive Immunotherapy Correlates with Therapy Response

Bartosz Grzywacz, MD, Elizabeth L. Courville, MD, David H. McKenna, MD, Jeffrey S. Miller, MD, Sarah Cooley, MD, Laura Moench, MD

Blood (2017) 130 (Supplement 1): 4459.

https://doi.org/10.1182/blood.V130.Suppl_1.4459.4459

Published: 2017

Journal Articles

Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models

Martin Felices, PhD, Craig E. Eckfeldt, MD PhD, Todd R Lenvik, Behiye Kodal, Alexander J. Lenvik, Laura Bendzick, Caitlin Ryan, Melissa A. Geller, Sarah Cooley, MD, Daniel J. Weisdorf, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2017) 130 (Supplement 1): 4465.

https://doi.org/10.1182/blood.V130.Suppl_1.4465.4465

Published: 2017

Journal Articles

Pre-Transplant Exhausted Marrow Infiltrating T Lymphocytes in MRD Negative Patients with Acute Leukemia Predict Early Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation

Robin Williams, MDMS, Sarah Cooley, MD, Peter M. Gordon, MDPhD, Veronika Bachanova, MD PhD, Daniel J. Weisdorf, MD, Bruce Blazar, MD, John E. Wagner, MD, Jeffrey S. Miller, MD, Michael R Verneris, MD

Blood (2017) 130 (Supplement 1): 1997.

https://doi.org/10.1182/blood.V130.Suppl_1.1997.1997

Published: 2017

Journal Articles

Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function

Frank Cichocki, PhD, Bahram Valamehr, PhD MBA, Dhifaf Sarhan, PhD, Bin Zhang, Sarah Cooley, MD, Michael R. Verneris, MD, Bruce R. Blazar, MD, Ryan Bjordahl, PhD, Betsy Rezner, BS, Paul Rogers, PhD, Chad Green, David H McKenna, MD, Daniel Shoemaker, PhD, Scott Wolchko, MS, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 1225.

https://doi.org/10.1182/blood.V128.22.1225.1225

Published: 2016

Journal Articles

A Novel HIV Envelope Bi-Specific Killer Engager Enhances Natural Killer Cell Mediated ADCC Responses Against HIV-Infected Cells

Zachary B. Davis, PhD BS, Todd Lenvik, Louis Hansen, Martin Felices, PhD, Sarah Cooley, MD, Dan Vallera, PhD, Ashley T. Haase, MD, Richard A. Koup, MD, Daniel Douek, MD, Timothy Schacker, MD, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 2517.

https://doi.org/10.1182/blood.V128.22.2517.2517

Published: 2016

Journal Articles

Continuous IL-15 Signaling Leads to Functional Exhaustion of Human Natural Killer Cells through Metabolic Changes That Alters Their In Vivo Anti-Tumor Activity

Martin Felices, PhD, Alexander Lenvik, Sami Chu, Ron McElmurry, Sarah Cooley, MD, Jakub Tolar, MD PhD, Bruce R. Blazar, MD, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 551.

https://doi.org/10.1182/blood.V128.22.551.551

Published: 2016

Journal Articles

Adaptive NK Cell Expansion Is Associated with Reduced Relapse of Lymphoid Malignancies after Autologous Hematopoietic Cell Transplant

Rohtesh S. Mehta, MD MPH, MS, Rose Wangen, Frank Cichocki, PhD, Martin Felices, PhD, Xianghua Luo, PhD, Daniel J. Weisdorf, MD, Michael R. Verneris, MD, Jeffrey S. Miller, MD, Sarah Cooley, MD

Blood (2016) 128 (22): 515.

https://doi.org/10.1182/blood.V128.22.515.515

Published: 2016

NARROW

Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)

Bortezomib-Based Consolidation/Maintenance Therapy for Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

iPSC-Derived NK Cells and Anti-PD-1 Antibody Synergize to Enhance T Cell Cytokine and Cytolytic Responses Against Multiple Tumors

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Outcomes of Pediatric Patients with Acute Leukemia Following Adult Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching

Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+ Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation

Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia

Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML

NK Cell Homing and Persistence in Bone Marrow after Adoptive Immunotherapy Correlates with Therapy Response

Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models

Pre-Transplant Exhausted Marrow Infiltrating T Lymphocytes in MRD Negative Patients with Acute Leukemia Predict Early Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation

Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function

A Novel HIV Envelope Bi-Specific Killer Engager Enhances Natural Killer Cell Mediated ADCC Responses Against HIV-Infected Cells

Continuous IL-15 Signaling Leads to Functional Exhaustion of Human Natural Killer Cells through Metabolic Changes That Alters Their In Vivo Anti-Tumor Activity

Adaptive NK Cell Expansion Is Associated with Reduced Relapse of Lymphoid Malignancies after Autologous Hematopoietic Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only